A novel drug for the most common cause of dwarfism accelerated children’s growth in a small but closely watched clinical trial, the company BridgeBio said Monday, advancing the latest treatment in ...

The Food and Drug Administration (FDA) has approved the first drug to treat the most common form of dwarfism, known as achondroplasia. BioMarin Pharmaceutical, a U.S.-based company, has been ...

With gene therapy, a cure for growth-hormone resistant dwarfism may be on the horizon. National University of Singapore, Yong Loo Lin School of Medicine Researchers from the NUS Yong Loo Lin School of ...

HAMPTON ROADS, Va. - Chandler Crews was born with achondroplasia, a serious, progressive, and lifelong condition that is the most common form of dwarfism. In 2010 at the age of 16, she made the choice ...

(Reuters) - BioMarin Pharmaceutical Inc's once-daily injection for children with the most common type of dwarfism received clearance from the U.S. health regulator on Friday, making it the first ...

In a retrospective study believed to be one of the largest of its kind, researchers say they have successfully charted the health risks, growth patterns, and medical and surgical outcomes of 1,374 ...

A drug that boosts bone growth in children with the most common form of dwarfism may also reduce their chances of sudden infant death syndrome, sleep apnea, and needing surgery, according to a new ...

BioMarin Pharmaceuticals Inc. BMRN stock is trading higher on Thursday as the company is celebrating positive results from its Phase 3 CANOPY-HCH-3 study for VOXZOGO (vosoritide) in children with ...

A genetic disorder that slows bone growth and leads to dwarfism now has an approved drug, a biologic therapy developed by BioMarin Pharmaceutical. The European Commission decision announced Friday ...